Výsledky vyhledávání

Autor: Weisel, K. Dimopoulos, M. Moreau, P. Yagci, M. Larocca, A. Kanate, A.S. Vural, F. Cascavilla, N. Basu, S. Johnson, P. Byeff, P. Hus, M. Rodríguez-Otero, P. Muelduer, E. Anttila, P. Hayden, P.J. Krauth, M.-T. Lucio, P. Ben-Yehuda, D. Mendeleeva, L. Guo, S. Yu, X. Grote, L. Biyukov, T. Dhanasiri, S. Richardson, P.

In the randomized phase-3 OPTIMISMM study, the addition of pomalidomide to bortezomib and low-dose dexamethasone (PVd) resulted in significant improvement in progression-free survival (PFS) in lenalidomide-pretreated patients with relapsed or refract

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::41c041b89dd6dd8f2b058a5b3da95a58
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078043

Zobrazit plný text záznamu

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Autor: Richardson, P.G. Oriol, A. Beksac, M. Liberati, A.M. Galli, M. Schjesvold, F. Lindsay, J. Weisel, K. White, D. Facon, T. San Miguel, J. Sunami, K. O'Gorman, P. Sonneveld, P. Robak, P. Semochkin, S. Schey, S. Yu, X. Doerr, T. Bensmaine, A. Biyukov, T. Peluso, T. Zaki, M. Anderson, K. Dimopoulos, M. Abildgaard, N. Adler, H. Altuntas, F. Akay, O.M. Amin, B. Anagnostopoulos, A. Anderson, L. Anttila, P. Araujo, C. Arce-Lara, C. Aydin, Y. Basu, S. Battini, R. Beeker, T. Benboubker, L. Ben-Yehuda, D. Bladé, J. Blau, I.W. Boccia, R. Burke, L. Byeff, P. Cascavilla, N. Cavo, M. Chantry, A. Charles, Y. Chaudhry, A. Corso, A. Coyne, M. De Arriba, F. Delimpasi, S. Desjardins, P. Dhakal, B. Di Bartolomeo, P. Di Raimondo, F. Dürig, J. Engelhardt, M. Escoffre-Barbe, M. Esteves, G. Flogegard, M. Gabrail, N. Gamberi, B. Garrison, M. Gay, J. Gisslinger, H. Goldschmidt, H. Goncalves, C. Gressot, L. Grosicki, S. Hanna, W. Hayden, P. Henriques Bernardo, M.M. Hermann, R. Holden, V. Honkalehto, K. Huben, M. Huffman, J. Hunter, H. Hus, M. Jagasia, M. Jagganath, S. Janakiram, M. Jaiyesimi, I. Jenner, M. João, C. Johnson, P. Jurcyszyn, A. Kalayoğlu Beşişik, S. Kambhampati, S. Kanate, A. Karadoğan, I. Khojasteh, A. Kirkel, D. Komarnicki, M. Krauth, M.-T. Kuriakose, P. Larocca, A. Lauri, B. Leleu, X. Lucio, P. Luppi, M. Mangiacavalli, S. Mariette, C. Matsue, K. Mellqvist, U.-H. Mendeleeva, L. Meshad, M. Miller, C. Mohrbacher, A. Moreau, P. Morelli, A.M. Müldür, E. Naassan, A. Nahi, H. Nair, R. O'Dwyer, M. Öngören Aydin, S. Openshaw, T. O'Rourke, T. Osswald, M. Overton, L. Pati, A. Pavic, M. Pegourie, B. Pehlivan, M. Pierola, A.A. Plesner, T. Pluta, A. Rabin, N. Ramasamy, K. Rambaldi, A. Rodriguez, P. Röllig, C. Rosenblatt, J. Rosenbluth, J. Salomo, M. Samoylova, O. Sastre Moral, J. Sati, H. Selleri, C. Shafeek, S. Shinagawa, A. Sleckman, B. Smith, C. Sonmez, M. Stone, C. Streetly, M. Suzuki, K. Taetle, R. Tafuri, A. Takezako, N. Teke, H.Ü. Vapaatalo, M. Vassilopoulos, G. Verma, A. Vidito, S. Viterbo, L. Vural, F. Wang, X.S. Yağci, M. Yee, A. OPTIMISMM trial investigators

Background: As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has sho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::60a64e8be607a2d94110070c4a87c17f
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3122238

Zobrazit plný text záznamu

Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study

Publikováno v: Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::2ebd6da012cdb67a8a5f9b05e3138d69
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2825

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis

Autor: Moreau, P. Dimopoulos, M.A. Richardson, P.G. Siegel, D.S. Cavo, M. Corradini, P. Weisel, K. Delforge, M. O'Gorman, P. Song, K. Chen, C. Bahlis, N. Oriol, A. Hansson, M. Kaiser, M. Anttila, P. Raymakers, R. Joao, C. Cook, G. Sternas, L. Biyukov, T. Slaughter, A. Hong, K. Herring, J. Yu, X. Zaki, M. San-Miguel, J.

Objectives: Heavily pretreated patients with relapsed and refractory multiple myeloma are susceptible to treatment-related adverse events (AEs). Managing AEs are important to ensure patients continue therapy long enough to receive the best clinical b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::2991ed8e1bdd4ac49a00f95368df13ea
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3125855

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Adverse Event (AE) Management With Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in the STRATUS(TM) Trial: A Phase 3b Study Evaluating Safety and Efficacy in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM)

Publikováno v: In Clinical Lymphoma Myeloma and Leukemia September 2015 15 Supplement 3:e264-e264

Zobrazit plný text záznamu

Akademický článek

STRATUS(TM) (MM 010): A Single Arm, Phase 3b Study Evaluating Safety and Efficacy of Pomalidomide (POM) + Low Dose Dexamethasone (LoDEX) in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM)

Autor: Dimopoulos, M.A., Palumbo, A., Corradini, P., Cavo, M., Delforge, M., Weisel, K., Ocio, E., Di Raimondo, F., Rollig, C., Oriol, A., Simcock, M., Miller, N., Slaughter, A., Biyukov, T., Peluso, T., Sternas, L., Zaki, M., Moreau, P.

Publikováno v: In Clinical Lymphoma Myeloma and Leukemia September 2015 15 Supplement 3:e76-e77

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání